Loading
A phase 3 trial of Tinengotinib in biliary tract cancer, run by TransThera Sciences (Nanjing), Inc., active and no longer recruiting.
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma is a phase 3 interventional study registered as NCT05948475 by TransThera Sciences (Nanjing), Inc., with 200 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2026-12. Interventions recorded: Tinengotinib 8 mg, Tinengotinib 10 mg and Physician's Choice.
Shares TransThera Sciences, Tinengotinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares TransThera Sciences, Tinengotinib, ctDNA-guided switching among FGFR inhibitors, Biliary tract cancer (cholangiocarcinoma).
Shares ctDNA-guided switching among FGFR inhibitors, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.